These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 2549606)

  • 41. Dual targeting of topoisomerase IV and gyrase to reduce mutant selection: direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin.
    Strahilevitz J; Hooper DC
    Antimicrob Agents Chemother; 2005 May; 49(5):1949-56. PubMed ID: 15855518
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The fluoroquinolones.
    Walker RC; Wright AJ
    Mayo Clin Proc; 1991 Dec; 66(12):1249-59. PubMed ID: 1749294
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Purification of pneumococcal type II topoisomerases and inhibition by gemifloxacin and other quinolones.
    Morrissey I; George JT
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():101-6. PubMed ID: 10824040
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Current Case of Quinolones: Synthetic Approaches and Antibacterial Activity.
    Naeem A; Badshah SL; Muska M; Ahmad N; Khan K
    Molecules; 2016 Mar; 21(4):268. PubMed ID: 27043501
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A class of gyrase mutants of Salmonella typhimurium show quinolone-like lethality and require rec functions for viability.
    Garí E; Figueroa-Bossi N; Blanc-Potard AB; Spirito F; Schmid MB; Bossi L
    Mol Microbiol; 1996 Jul; 21(1):111-22. PubMed ID: 8843438
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Gyrase inhibitor].
    Forth W
    Klin Wochenschr; 1985 Oct; 63(19):1036-9. PubMed ID: 2999503
    [No Abstract]   [Full Text] [Related]  

  • 47. Quinolone pharmacokinetics in the elderly.
    Schentag JJ; Goss TF
    Am J Med; 1992 Apr; 92(4A):33S-37S. PubMed ID: 1316067
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Quinolone mode of action--new aspects.
    Hooper DC
    Drugs; 1993; 45 Suppl 3():8-14. PubMed ID: 7689456
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Chemical evolution of the fluoroquinolone antimicrobial agents.
    Neu HC
    Am J Med; 1989 Dec; 87(6C):2S-9S. PubMed ID: 2557762
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mode of action of the quinolone antimicrobial agents: review of recent information.
    Hooper DC; Wolfson JS
    Rev Infect Dis; 1989; 11 Suppl 5():S902-11. PubMed ID: 2549608
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mammalian topoisomerase II inhibitory activity of 1-cyclopropyl-6,8- difluoro-1,4-dihydro-7-(2,6-dimethyl-4-pyridinyl)-4-oxo-3-quinolinecarb oxylic acid and related derivatives.
    Wentland MP; Lesher GY; Reuman M; Gruett MD; Singh B; Aldous SC; Dorff PH; Rake JB; Coughlin SA
    J Med Chem; 1993 Sep; 36(19):2801-9. PubMed ID: 8410993
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Gyrase inhibitors. Central nervous side effects and inhibition of methylxanthine elimination].
    Harder S; Shah PM; Staib AH
    Dtsch Med Wochenschr; 1990 Feb; 115(7):270-3. PubMed ID: 2406120
    [No Abstract]   [Full Text] [Related]  

  • 53. Characterization of Salmonella Typhimurium DNA gyrase as a target of quinolones.
    Kongsoi S; Yokoyama K; Suprasert A; Utrarachkij F; Nakajima C; Suthienkul O; Suzuki Y
    Drug Test Anal; 2015 Aug; 7(8):714-20. PubMed ID: 25381884
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Quinolone antibacterials: synthesis and biological activity of carbon isosteres of the 1-piperazinyl and 3-amino-1-pyrrolidinyl side chains.
    Laborde E; Kiely JS; Culbertson TP; Lesheski LE
    J Med Chem; 1993 Jul; 36(14):1964-70. PubMed ID: 8393112
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Usual and unusual antibacterial effects of quinolones.
    Furet YX; Pechère JC
    J Antimicrob Chemother; 1990 Oct; 26 Suppl B():7-15. PubMed ID: 2175306
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Molecular mechanisms of drug inhibition of DNA gyrase.
    Lewis RJ; Tsai FT; Wigley DB
    Bioessays; 1996 Aug; 18(8):661-71. PubMed ID: 8760340
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Type II topoisomerases as targets for quinolone antibacterials: turning Dr. Jekyll into Mr. Hyde.
    Anderson VE; Osheroff N
    Curr Pharm Des; 2001 Mar; 7(5):337-53. PubMed ID: 11254893
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mechanisms of action and resistance of older and newer fluoroquinolones.
    Hooper DC
    Clin Infect Dis; 2000 Aug; 31 Suppl 2():S24-8. PubMed ID: 10984324
    [TBL] [Abstract][Full Text] [Related]  

  • 59. New quinolones: in vitro effects as a potential source of clinical toxicity.
    Forsgren A; Bredberg A; Riesbeck K
    Rev Infect Dis; 1989; 11 Suppl 5():S1382-9. PubMed ID: 2549607
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mechanism of action of the des-F(6) quinolone BMS-284756 measured by supercoiling inhibition and cleavable complex assays.
    Wu P; Lawrence LE; Denbleyker KL; Barrett JF
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3660-2. PubMed ID: 11709365
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.